Madrigal Pharmaceuticals (MDGL) Reiterated at Market Outperform by Citizens

June 1, 2026 4:42 AM

Citizens analyst Jonathan Wolleben reiterated a Market Outperform rating and $737.00 price target on Madrigal Pharmaceuticals (NASDAQ: MDGL).The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found